Tirzepatide in Australia: verification guide

Tirzepatide (Mounjaro / Zepbound) is the most-tested compound on LabDoc. Both compounded-pharmacy and research-grade supply exist in Australia, with very different verification expectations.

Two supply chains, two verification standards

Compounded tirzepatide dispensed by an Australian pharmacy under a valid prescription is prepared and supplied under applicable professional and regulatory requirements and carries pharmacist accountability. Independent testing can still provide batch-specific information about identity, purity, and content.

Research-grade tirzepatide from grey-market vendors has no such guarantees. Both identity and content must be verified per batch.

What a clean tirzepatide CoA shows

• LC-MS identity matching tirzepatide monoisotopic mass (~4811 Da).
• HPLC purity ≥ 97%, single dominant peak.
• Quantitative HPLC content within ±10% of label claim.
• Endotoxin and bioburden results if the vendor markets the product as injectable-grade.

Most common failures

1. Under-fill at the 10 mg and 15 mg vial sizes.
2. Semaglutide substitution: cheaper to source, similar physiological effect, undetectable without LC-MS.
3. Stability degradation in vials shipped without cold-chain.

Verifying your vendor

Check tirzepatide purity results and the vendor's Verified status. If you can't find independent data for the specific batch, submit a vial via Submit a CoA or order a fresh test through Sample Testing.